Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 478516

Adiponectin is Decreased in Insulin-treated Type 2 Diabetic Patients Compared to Those on Oral Hypoglycemic Drugs


Ljubic, Spomenka; Piljac, Ante; Novak, Branko; Kerum, Tanja; Boras, Jozo
Adiponectin is Decreased in Insulin-treated Type 2 Diabetic Patients Compared to Those on Oral Hypoglycemic Drugs // Diabetes
New York (NY), 2010. (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 478516 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Adiponectin is Decreased in Insulin-treated Type 2 Diabetic Patients Compared to Those on Oral Hypoglycemic Drugs

Autori
Ljubic, Spomenka ; Piljac, Ante ; Novak, Branko ; Kerum, Tanja ; Boras, Jozo

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Diabetes / - New York (NY), 2010

Skup
70th American Diabetes Association Scientific Session

Mjesto i datum
Orlando (FL), Sjedinjene Američke Države, 25.06.2010. - 29.06.2010

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
adiponectin; insulin-therapy; type II diabetes; inflammatory markers

Sažetak
Adiponectin (ApN) was studied in type 2 diabetic patients on oral hypoglycemic drugs (DM2) and insulin (DM3), and in type 1 patients (DM1). We determined ApN, C-reactive protein (CRP), fibrinogen (FIB), homocysteine (HCY), fasting plasma glucose (fPG), glycated hemoglobin (A1c), systolic (SBP) and diastolic (DBP) blood pressure, liver function tests, lipid values, uric acid (UA), and albumin/creatinine (A/C) ratio in 248 patients. DM3 group had been on insulin ≥2 years. A significant among-group difference was found in ApN (DM1 vs DM2 vs DM3 = 14.22±11.64 vs 8.23±5.55 vs 4.87±2.23 ; ANOVA: F=11.46, df=2, p<0.0001), CRP (DM1 vs DM2 vs DM3 = 2.04±2.52 vs 4.02±5.62 vs 2.07±2.12 ; F=7.17, df=2, p=0.027), high density lipoprotein (HDL) (DM1 vs DM2 vs DM3 = 1.69±0.31 vs 1.38±0.37 vs 1.59±0.24 ; F=13.93, df=2, p<0.001), UA (DM1 vs DM2 vs DM3 = 255.12±68.3 vs 336.4±87.1 vs 312.9±139.02 ; F=14.45, df=2, p<0.001) and BMI (DM1 vs DM2 vs DM3 = 24.20±3.06 vs 30.35±6.02 vs 28.81±4.18 ; F=11.91, df=2, p<0.0001), but not in FIB and HCY. Tukey post hoc test showed a significant difference (p<0.05) in ApN between DM1 and DM2, DM1 and DM3, and DM2 and DM3, but not in BMI (p=0.13), CRP (p=0.23), UA (p=0.38) and HDL (p=0.92) between DM2 and DM3. In DM1 the best model (R2=0.952) for ApN included FIB (R2=0.45, p<0.001), fPG (R2=0.38, p<0.01) and ALT (R2=0.11, p=0.03) ; in DM2 it included HDL (R2=0.55, p<0.0001) and ALT (R2=0.32, p<0.001), and in DM3 HDL (R2=0.65, p=0.002) and UA (R2=0.31, p=0.007). In DM1 ApN correlated significantly (p<0.05) with BMI (r=-0.40) and HDL (r=0.40), in DM2 (p<0.05) with HDL (r=0.57), ALT (-r=0.39) and A/C ratio (r=0.51), and in DM3 (p<0.05) with fPG (r=0.56), CRP (r=0.41), FIB (r=0.67) and HDL (r= 0.55). Duration of insulin therapy did not correlate with ApN in DM3 (p=0.84). ApN was decreased in DM3 compared to DM2, which could be due to a suppressive effect of insulin on ApN production in adipocytes. This suggests a possible increased risk of vascular disease in these patients. HDL was among the main predictors of ApN. In DM3 it was not decreased, while CRP was not increased, which could be beneficial in vascular protection.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekti:
045-0450961-0958 - Uloga adiponektina i upalnih čimbenika u razvoju komplikacija šećerne bolesti (Ljubić, Spomenka, MZOS ) ( CroRIS)

Ustanove:
Klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac

Profili:

Avatar Url Jozo Boras (autor)

Avatar Url Spomenka Ljubić (autor)


Citiraj ovu publikaciju:

Ljubic, Spomenka; Piljac, Ante; Novak, Branko; Kerum, Tanja; Boras, Jozo
Adiponectin is Decreased in Insulin-treated Type 2 Diabetic Patients Compared to Those on Oral Hypoglycemic Drugs // Diabetes
New York (NY), 2010. (poster, međunarodna recenzija, sažetak, znanstveni)
Ljubic, S., Piljac, A., Novak, B., Kerum, T. & Boras, J. (2010) Adiponectin is Decreased in Insulin-treated Type 2 Diabetic Patients Compared to Those on Oral Hypoglycemic Drugs. U: Diabetes.
@article{article, author = {Ljubic, Spomenka and Piljac, Ante and Novak, Branko and Kerum, Tanja and Boras, Jozo}, year = {2010}, keywords = {adiponectin, insulin-therapy, type II diabetes, inflammatory markers}, title = {Adiponectin is Decreased in Insulin-treated Type 2 Diabetic Patients Compared to Those on Oral Hypoglycemic Drugs}, keyword = {adiponectin, insulin-therapy, type II diabetes, inflammatory markers}, publisherplace = {Orlando (FL), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }
@article{article, author = {Ljubic, Spomenka and Piljac, Ante and Novak, Branko and Kerum, Tanja and Boras, Jozo}, year = {2010}, keywords = {adiponectin, insulin-therapy, type II diabetes, inflammatory markers}, title = {Adiponectin is Decreased in Insulin-treated Type 2 Diabetic Patients Compared to Those on Oral Hypoglycemic Drugs}, keyword = {adiponectin, insulin-therapy, type II diabetes, inflammatory markers}, publisherplace = {Orlando (FL), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font